Roswitha Verwer explores whether the term FemTech helps or limits women’s healthcare, and why the future must move beyond visibility toward full integration in mainstream medicine.

Roswtha Verwer explores how delayed diagnosis in reproductive health drives emotional, financial, and clinical costs, and how earlier biological insight can reduce failed fertility cycles and unnecessary escalation.

Roswitha Verwer shares why YON E is closing its seed readiness round, how funding will support prototype completion, clinical trial preparation, regulatory readiness, and the next phase of women’s health diagnostics.

YON E is preparing for launch by listening first. Through voice-of-customer research with 400+ women, clinician conversations, community engagement, and pricing validation, we are building a women’s health platform rooted in real demand, clinical relevance, and objective daily insights into cycle, fertility, and vaginal health.